The efficacy of infliximab for patients with rheumatoid arthritis in Japan: results of 5000 cases by post-marketing surveillance data

Aim:  To clarify the efficacy of infliximab (INF) for active rheumatoid arthritis (RA) in Japan by nationwide postmarketing surveillance (PMS) data. Method:  The data of 5000 cases with active RA, despite treatment with methotrexate, were collected to Tanabe Seiyaku Co., Ltd and all of these were an...

Full description

Saved in:
Bibliographic Details
Published inAPLAR journal of rheumatology Vol. 9; no. 2; pp. 142 - 145
Main Authors OKA, Hiroshi, NISHIOKA, Kusuki, TOGO, Masanori, OCHI, Takahiro
Format Journal Article
LanguageEnglish
Published Melbourne, Australia Blackwell Publishing Asia 01.08.2006
Subjects
infliximab
multicentre study
pneumonia
postmarketing surveillance
rheumatoid arthritis
Online AccessGet full text

Cover

More Information
Summary:Aim:  To clarify the efficacy of infliximab (INF) for active rheumatoid arthritis (RA) in Japan by nationwide postmarketing surveillance (PMS) data. Method:  The data of 5000 cases with active RA, despite treatment with methotrexate, were collected to Tanabe Seiyaku Co., Ltd and all of these were analysed in detail for efficacy and adverse reactions. Overall efficacy was evaluated by physicians to three grades: markedly improved, improved and unchanged. Results:  Overall efficacy was 34.0% markedly improved, 57.6% improved and 8.4% unchanged at 22 weeks after INF therapy, respectively. Overall of adverse reactions were 28.0% and serious adverse reactions were 6.2%. Conclusion:  Iinfliximab was proven to be very effective and safe by nationwide PMS data in Japan. Longer observation is needed for further evaluation of INF therapy, especially efficacy forpreventing joint damage.
Bibliography:istex:0407A75C79E64BC9B96E009689F4A30B96ECC244
ark:/67375/WNG-PJ43R7T5-7
ArticleID:APL198
ISSN:0219-0494
1479-8077
DOI:10.1111/j.1479-8077.2006.00198.x